Ronak Shah

11.8k total citations · 1 hit paper
32 papers, 1.9k citations indexed

About

Ronak Shah is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Ronak Shah has authored 32 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Cancer Research, 11 papers in Oncology and 9 papers in Pathology and Forensic Medicine. Recurrent topics in Ronak Shah's work include Cancer Genomics and Diagnostics (16 papers), Genetic factors in colorectal cancer (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). Ronak Shah is often cited by papers focused on Cancer Genomics and Diagnostics (16 papers), Genetic factors in colorectal cancer (8 papers) and Colorectal Cancer Treatments and Studies (5 papers). Ronak Shah collaborates with scholars based in United States, India and Australia. Ronak Shah's co-authors include Michael F. Berger, Nikolaus Schultz, Sasinya N. Scott, Tihana Ibrahimpašić, Snjezana Doğan, Iñigo Landa, Ian Ganly, Julio C. Ricarte‐Filho, Rileen Sinha and James A. Fagin and has published in prestigious journals such as Journal of Clinical Investigation, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Ronak Shah

29 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers

2016 862 citations Iñigo Landa, Tihana Ibrahimpašić et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Ronak Shah

Since Specialization

Citations

This map shows the geographic impact of Ronak Shah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronak Shah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronak Shah more than expected).

Fields of papers citing papers by Ronak Shah

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronak Shah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronak Shah. The network helps show where Ronak Shah may publish in the future.

Co-authorship network of co-authors of Ronak Shah

This figure shows the co-authorship network connecting the top 25 collaborators of Ronak Shah. A scholar is included among the top collaborators of Ronak Shah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronak Shah. Ronak Shah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance) 2025 ·European Urology Open Science ·Brendan J. Guercio, Karissa Whiting, Ronak Shah, Karla V. Ballman, Susan Halabi, Ashley Marie Regazzi, Jennifer H. Milbank, Dean F. Bajorin, Himisha Beltran, Michael J. Morris, David B. Solit, (unknown), Gopa Iyer, Venkatraman Seshan, Jonathan E. Rosenberg	0
2	Exploratory analysis of CTDNA and imaging response in Phase I/II chorus study of canakinumab with chemoradiation and durvalumab for NSCLC 2024 ·(unknown), (unknown), Michael Offin, Daphna Y. Gelblum, Fernando C. Santini, (unknown), Michael Berger, Ronak Shah, Daniel R. Gomez, Jamie E. Chaft	1
3	Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study 2024 ·Clinical Cancer Research ·James W. Smithy, (unknown), (unknown), Ronak Shah, Matthew Adamow, (unknown), (unknown), (unknown), (unknown), Alexander N. Shoushtari, Allison Betof Warner, Margaret K. Callahan, Parisa Momtaz, Omar Eton, Suresh Nair, Jedd D. Wolchok, Paul B. Chapman, Michael F. Berger, Katherine S. Panageas, Michael A. Postow	4
4	Clinical utility of plasma cell-free DNA in pancreatic neuroendocrine neoplasms 2024 ·Endocrine Related Cancer ·(unknown), Ronak Shah, Joanne F. Chou, Ritika Kundra, (unknown), (unknown), (unknown), (unknown), Michael F. Berger, Diane Reidy‐Lagunes, Nitya Raj	2
5	High-risk and silent clonal hematopoietic genotypes in patients with nonhematologic cancer 2023 ·Blood Advances ·Aaron J. Stonestrom, Kamal Menghrajani, Sean M. Devlin, Sebastià Franch‐Expósito, Ryan Ptashkin, (unknown), Barbara Spitzer, Xiaodi Wu, Justin Jee, (unknown), Jennifer H. Milbank, Ronak Shah, Abhinita Mohanty, A. Rose Brannon, Wenbin Xiao, Michael F. Berger, Simon Mantha, Ross L. Levine	5
6	Assessing the utility of a cell-free tumor (ct)DNA assay (MSK-ACCESS) in patients (pts) with node-positive (N+) muscle-invasive bladder cancer (MIBC) undergoing neoadjuvant chemotherapy (NAC). 2023 ·Journal of Clinical Oncology ·Andrew Katims, Andrew T. Lenis, Ronak Shah, Carissa Chu, (unknown), Ashley Marie Regazzi, Eugene J. Pietzak, David H. Aggen, Samuel A. Funt, Min Yuen Teo, Jonathan E. Rosenberg, Dean F. Bajorin, Timothy F. Donahue, Bernard H. Bochner, Michael F. Berger, David B. Solit, Gopa Iyer	1
7	FaceReZero Transformer for Unbiased Occlusion Invariant Deep Face Recognition with Train-Time Augmentations 2023 ·Ronak Shah, (unknown), (unknown), (unknown), (unknown)	0
8	Mechanisms of acquired resistance to TRK inhibitors. 2022 ·Journal of Clinical Oncology ·Guilherme Harada, Noura J. Choudhury, Alison M. Schram, Ezra Y. Rosen, Yonina R. Murciano‐Goroff, Christina J. Falcon, Clare Wilhelm, (unknown), Dazhi Liu, Jason C. Chang, Soo‐Ryum Yang, (unknown), (unknown), (unknown), (unknown), Ronak Shah, Emiliano Cocco, Alexander Drilon	11
9	Ancient Sanskrit Line-level OCR using OpenNMT Architecture 2021 ·Ronak Shah, (unknown), Ajai Kumar	7
10	Abstract PR07: MSI detection in plasma cfDNA: MSI as a marker of disease burden 2020 ·Clinical Cancer Research ·(unknown), Alicia Latham, Zalak Patel, (unknown), Maysun Hasan, Juber Patel, (unknown), Ronak Shah, Fanli Meng, Xiaohong Jing, (unknown), (unknown), Andrea Cercek, Ahmet Zehir, Brian Houck‐Loomis, Dana W.Y. Tsui, Zsofia K. Stadler, Michael F. Berger	1
11	<p>Precision oncology: lessons learned and challenges for the future</p> 2019 ·Cancer Management and Research ·Hsih‐Te Yang, Ronak Shah, David Tegay, Kenan Onel	9
12	Real-Time Genomic Characterization of Metastatic Pancreatic Neuroendocrine Tumors Has Prognostic Implications and Identifies Potential Germline Actionability 2018 ·JCO Precision Oncology ·Nitya Raj, Ronak Shah, Zsofia K. Stadler, Semanti Mukherjee, Joanne F. Chou, Brian R. Untch, Janet Li, (unknown), (unknown), Leonard B. Saltz, Diana Mandelker, Marc Ladanyi, Michael F. Berger, David S. Klimstra, Diane Reidy‐Lagunes	65
13	Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers breakdown → 2016 ·Journal of Clinical Investigation ·Iñigo Landa, Tihana Ibrahimpašić, Laura Boucai, Rileen Sinha, Jeffrey A. Knauf, Ronak Shah, Snjezana Doğan, Julio C. Ricarte‐Filho, Gnana P. Krishnamoorthy, Bin Xu, Nikolaus Schultz, Michael F. Berger, Chris Sander, Barry S. Taylor, Ronald Ghossein, Ian Ganly, James A. Fagin	862
14	The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes 2016 ·Modern Pathology ·Olca Baştürk, Marcus Tan, Umesh Bhanot, Peter J. Allen, Volkan Adsay, Sasinya N. Scott, Ronak Shah, Michael F. Berger, Gokce Askan, Esra Dikoglu, Vaidehi Jobanputra, Kazimierz O. Wrzeszczyński, Carlie Sigel, Christine A. Iacobuzio–Donahue, David S. Klimstra	68
15	Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2) 2015 ·Modern Pathology ·Jaclyn F. Hechtman, Weiguo Liu, Justyna Sadowska, (unknown), Laetitia Borsu, Maria E. Arcila, Helen Won, Ronak Shah, Michael F. Berger, Efsevia Vakiani, Jinru Shia, David S. Klimstra	49
16	Comprehensive mutation profiling by next‐generation sequencing of effusion fluids from patients with high‐grade serous ovarian carcinoma 2015 ·Cancer Cytopathology ·Ronak Shah, Sasinya N. Scott, A. Rose Brannon, Douglas A. Levine, Oscar Lin, Michael F. Berger	24
17	Methodology for designing and creating Hindi speech corpus 2015 ·(unknown), (unknown), (unknown), Ronak Shah, (unknown), (unknown)	7
18	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder 2014 ·European Urology ·Philip H. Kim, K. Eugene, John P. Sfakianos, Gopa Iyer, Emily C. Zabor, Sasinya N. Scott, Irina Ostrovnaya, Ricardo J. Ramirez, Arony Sun, Ronak Shah, (unknown), Victor E. Reuter, Dean F. Bajorin, Jonathan E. Rosenberg, Nikolaus Schultz, Michael F. Berger, Hikmat Al‐Ahmadie, David B. Solit, Bernard H. Bochner	105
19	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary 2014 ·Nature Genetics ·Petar Jelinic, Jennifer J. Mueller, Narciso Olvera, Fanny Dao, Sasinya N. Scott, Ronak Shah, (unknown), Nikolaus Schultz, Mithat Gönen, Robert A. Soslow, Michael F. Berger, Douglas A. Levine	266
20	Detecting Somatic Genetic Alterations in Tumor Specimens by Exon Capture and Massively Parallel Sequencing 2013 ·Journal of Visualized Experiments ·Helen Won, Sasinya N. Scott, A. Rose Brannon, Ronak Shah, Michael F. Berger	44

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact